ARTIVA BIOTHERAPEUTICS INC. - COMMON STOCK

Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

28 Apr 2025 16:35:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

08 Apr 2025 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

31 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

24 Mar 2025 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

20 Feb 2025 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D.

29 Jan 2025 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

12 Nov 2024 16:05:01 By Nasdaq GlobeNewswire

Artiva Biotherapeutics to Participate in the Jefferies London Healthcare Conference

11 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics Appoints Alison Moore, Ph.D., to Its Board of Directors

22 Oct 2024 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics to Participate in the 2024 Cantor Fitzgerald Global Healthcare Conference

10 Sep 2024 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

29 Aug 2024 16:05:00 By Nasdaq GlobeNewswire

Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering

18 Jul 2024 19:08:52 By Nasdaq GlobeNewswire